Recent Leukemia News

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia (June 20, 2017)

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML... Continue Reading

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia (June 14, 2017)

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The... Continue Reading

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients (June 5, 2017)

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic... Continue Reading

Have a Question about Chronic Myeloid Leukemia? Join us on May 25th! (May 2, 2017)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Luskin CancerConnect announces the opportunity to engage with leukemia expert, Marlise Luskin, MD, MSCE. On May 25th, 2017,... Continue Reading

Roswell Park Researchers Offer Novel Insight into Genetic Changes Leading to Cancer (January 17, 2017)

Findings may lead to personalized prognostic tests for blood disorders Predisposition to cancer and cancer progression can result from gene mutations that cause elevated rates of genetic damage. Similarly,... Continue Reading

FDA Grants Iclusig® Expanded Approval for CML (December 14, 2016)

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive... Continue Reading

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published... Continue Reading

FDA Priority Review Granted for Midostaurin in Leukemia (November 17, 2016)

The United States Food and Drug Administration (FDA) has granted priority review to PKC412 (midostaurin) in the treatment of newly diagnosed acute myeloid leukemia (AML) with the FLT3 mutation, as well... Continue Reading

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia (September 26, 2016)

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience... Continue Reading

Inotuzumab Ozogamicin Improves Progression-Free Survival in Acute Leukemia (September 6, 2016)

The investigative agent, inotuzumab ozogamicin, significantly improves progression-free survival and 2-year survival rates among patients with acute lymphoblastic leukemia that has stopped responding to... Continue Reading

« Previous PageNext Page »